# Atezolizumab Trial in Endometrial Cancer - AtTEnd

> **NCT03603184** · PHASE3 · COMPLETED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 549 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Placebos
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03603184
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-02
- **Primary completion:** 2025-01-20
- **Final completion:** 2025-01-20
- **Target enrollment:** 549 (ACTUAL)
- **Last updated:** 2025-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03603184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03603184, "Atezolizumab Trial in Endometrial Cancer - AtTEnd". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03603184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*